Boston Scientific Corporation
BSX
Rang in aandelen
#409
Deze bedrijfsbeschrijving is alleen in het Engels beschikbaar.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Aandeelprijs
$41.88
Laatst gesynchroniseerd: 2026-10-30
Marktkapitalisatie
$60.69B
Verandering (1 dag)
-1.89%
Verandering (1 jaar)
-58.42%
Land
US
Aandelendata: Financial Modeling Prep·Bijgewerkt op ·Geen beleggingsadvies·Zo rekenen we
Handel Boston Scientific Corporation (BSX)
Categorie
Healthcare
Operationele marge voor Boston Scientific Corporation (BSX)
Operationele marge op November 2026 TTM: 21.05%
Volgens de meest recente financiële rapporten en aandelenkoers van Boston Scientific Corporation is de huidige operationele marge (TTM) 21.05%. Eind 2025 had het bedrijf een operationele marge van 19.78%.
Geschiedenis van de operationele marge van Boston Scientific Corporation van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Verandering |
|---|---|---|
| 2026 (TTM) | 21.05% | 6.42% |
| 2025 | 19.78% | 25.75% |
| 2024 | 15.73% | 2.68% |
| 2023 | 15.32% | 6.54% |
| 2022 | 14.38% | -11.07% |
| 2021 | 16.17% | 166.83% |
| 2020 | 6.06% | -62.01% |
| 2019 | 15.95% | -9.79% |
| 2018 | 17.68% | 4.93% |
| 2017 | 16.85% | 14.31% |
| 2016 | 14.74% | 39.45% |
| 2015 | 10.57% | -7.69% |
| 2014 | 11.45% | -6.07% |
| 2013 | 12.19% | -11.09% |
| 2012 | 13.71% | -6.92% |
| 2011 | 14.73% | 7.13% |
| 2010 | 13.75% | -13.58% |
| 2009 | 15.91% | -1.12% |
| 2008 | 16.09% | 13.95% |
| 2007 | 14.12% | -10.58% |
| 2006 | 15.79% | -50.98% |
| 2005 | 32.21% | 2.29% |
| 2004 | 31.49% | 57.06% |
| 2003 | 20.05% | -4.07% |
| 2002 | 20.90% | 458.82% |
| 2001 | 3.74% | -85.24% |
| 2000 | 25.34% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 15.24% | -99.28% |
US
|
|
| 18.08% | -99.14% |
IE
|
|
| 21.25% | -98.99% |
US
|
|
| 14.84% | -99.30% |
DE
|
|
| 28.09% | -98.67% |
US
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.
Vragen over de operationele marge van Boston Scientific Corporation
Wat is de operationele marge van Boston Scientific Corporation?
Per nov. 2026 bedraagt de operationele marge van Boston Scientific Corporation 21.05%.
Wat was de operationele marge van Boston Scientific Corporation in 2025?
In 2025 bedroeg de operationele marge van Boston Scientific Corporation 19.78%, tegenover 15.73% in 2024.
Hoe heeft de operationele marge van Boston Scientific Corporation zich sinds 2020 ontwikkeld?
Tussen 2020 en 2025 was de operationele marge van Boston Scientific Corporation het hoogst in 2025 (19.78%) en het laagst in 2020 (6.06%).
Hoe verhoudt de operationele marge van Boston Scientific Corporation zich tot vergelijkbare bedrijven?
Bij Boston Scientific Corporation is de operationele marge (21.05%) hoger dan bij 3 van de 5 vergelijkbare bedrijven in de lijst hierboven. Van die bedrijven heeft Edwards Lifesciences Corporation de hoogste waarde: 28.09%.